加拿大卫生部批准Keytruda Sc™——帕博利珠单抗皮下制剂覆盖多癌种适应症

美股速递
Feb 18

加拿大卫生监管机构已正式批准Keytruda Sc™(帕博利珠单抗皮下制剂)用于多种癌症适应症。这一批准为患者提供了更为便捷的治疗选择,有望改善治疗体验。

该皮下制剂由默沙东(Merck)开发,旨在缩短给药时间并减少医疗资源占用。其获批适应症涵盖多个癌种,标志着免疫治疗领域的重要进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10